153 related articles for article (PubMed ID: 35106276)
41. The impact on clinical outcomes and healthcare resources from discontinuing colonoscopy surveillance subsequent to low-risk adenoma removal: A simulation study using the OncoSim-Colorectal model.
Steer KJ; Sun Z; Sadowski DC; Yong JHE; Coldman A; Nemecek N; Yang H
J Med Screen; 2024 Jun; 31(2):78-84. PubMed ID: 37728194
[TBL] [Abstract][Full Text] [Related]
42. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA
Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091
[TBL] [Abstract][Full Text] [Related]
43. Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing.
Roth JA; deVos T; Ramsey SD
Am Health Drug Benefits; 2019 Sep; 12(5):256-262. PubMed ID: 32015794
[TBL] [Abstract][Full Text] [Related]
44. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
45. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
46. Clinical evaluation of a multitarget fecal immunochemical test-sDNA test for colorectal cancer screening in a high-risk population: a prospective, multicenter clinical study.
Hu YT; Chen XF; Zhai CB; Yu XT; Liu G; Xiong ZG; Wang ZQ; Cai SJ; Li WC; Kong XX; Xiao Q; Wang CH; Tao ZH; Niu LY; Men JL; Wang Q; Wei SZ; Hu JJ; Yang TH; Peng JJ; Jiang GZ; Lv N; Chen YY; Zheng S; Gu YH; Ding KF
MedComm (2020); 2023 Aug; 4(4):e345. PubMed ID: 37576863
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness analysis of single colonoscopy versus single fecal test for colorectal cancer diagnosis and treatment.
Ishibashi F; Suzuki S; Kobayashi K; Tanaka R; Kawakami T; Mochida K; Nagai M; Ishibashi Y; Morishita T
J Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38348570
[TBL] [Abstract][Full Text] [Related]
48. CMOST: an open-source framework for the microsimulation of colorectal cancer screening strategies.
Prakash MK; Lang B; Heinrich H; Valli PV; Bauerfeind P; Sonnenberg A; Beerenwinkel N; Misselwitz B
BMC Med Inform Decis Mak; 2017 Jun; 17(1):80. PubMed ID: 28583127
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis of colorectal cancer screening in Shanghai, China: A modelling study.
Wang J; de Jonge L; Cenin DR; Li P; Tao S; Yang C; Yan B; Lansdorp-Vogelaar I
Prev Med Rep; 2022 Oct; 29():101891. PubMed ID: 35864929
[TBL] [Abstract][Full Text] [Related]
50. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
[No Abstract] [Full Text] [Related]
51. The impact of multi-target stool DNA testing in clinical practice in the United States: A real-world evidence retrospective study.
Miller-Wilson LA; Limburg P; Helmueller L; João Janeiro M; Hartlaub P
Prev Med Rep; 2022 Dec; 30():102045. PubMed ID: 36531100
[TBL] [Abstract][Full Text] [Related]
52. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy.
Haug U; Brenner H
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):422-8. PubMed ID: 15734968
[TBL] [Abstract][Full Text] [Related]
53. Serrated Polyp Yield at Colonoscopy in Patients with Positive FIT, Positive mt-sDNA, and Colonoscopy Only: Data from the New Hampshire Colonoscopy Registry.
Anderson JC; Hisey WM; Robinson CM; Limburg PJ; Kneedler BL; Butterly LF
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):226-232. PubMed ID: 36409472
[TBL] [Abstract][Full Text] [Related]
54. Colon Cancer Screening - Is It Time Yet?
Bhurgri H; Samiullah S
J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
[TBL] [Abstract][Full Text] [Related]
55. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
[TBL] [Abstract][Full Text] [Related]
56. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals.
Benamouzig R; Barré S; Saurin JC; Leleu H; Vimont A; Taleb S; De Bels F
Therap Adv Gastroenterol; 2021; 14():17562848211002359. PubMed ID: 33953799
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
